Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30768042 | 0.99 | KDM4E (0.34) | KDM4EALDH1A1ALOX15HSD17B10TSHR | |
| SCHEMBL24713633 | 0.91 | TNKS (0.36) | KDM4EALDH1A1ALOX15HSD17B10TSHR | |
| SCHEMBL29826476 | 0.90 | KDM4E (0.35) | KDM4EALDH1A1ALOX15HSD17B10TSHR | |
| SCHEMBL24714348 | 0.90 | KDM4E (0.35) | KDM4EALDH1A1ALOX15HSD17B10TSHR | |
| SCHEMBL1637326 | 0.83 | CSNK2A2 (0.37) | KDM4EALDH1A1ALOX15HSD17B10TSHR | |
| SCHEMBL1639065 | 0.81 | PIK3CB (0.52) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL23887207 | 0.81 | PIK3CA (0.37) | CCNE2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL24713822 | 0.80 | KDM4E (0.35) | KDM4EALDH1A1ALOX15HSD17B10TSHR | |
| SCHEMBL23887120 | 0.80 | CCNE2 (0.33) | GPR35CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL30434136 | 0.80 | SIRT2 (0.38) | ALDH1A1GPR35CCNE2CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC (US) | 2024-05-23 | — | — | US | disclosed |
| CN-117615763-A | Phosphoinositide 3 kinase beta inhibitor, composition and preparation method thereof | 健道生物医药有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-4284375-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Geode Therapeutics Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022164812-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-9718800-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-9718800-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20160060240-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-03-03 | — | — | US | disclosed |
| US-20160060240-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-03-03 | — | — | US | disclosed |
| EP-2493870-B1 | CHROMENONE DERIVATIVES WITH ANTI -TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2014-12-17 | — | — | EP | disclosed |
| US-20140194419-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2014-07-10 | — | — | US | disclosed |
| US-20140194419-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2014-07-10 | — | — | US | disclosed |
| US-8673906-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2014-03-18 | — | — | US | disclosed |
| US-8673906-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2014-03-18 | — | — | US | disclosed |
| US-8399460-B2 | Chromenone derivatives | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399460-B2 | Chromenone derivatives | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098271-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | KDM4E 2576/4885ALDH1A1 1233/4885ALOX15 2530/4885 |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | KDM4E 2576/4885ALDH1A1 1233/4885ALOX15 2530/4885 |
| US-20140194419-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | KDM4E 2576/4885ALDH1A1 1233/4885ALOX15 2530/4885 |
| US-20160060240-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | KDM4E 2576/4885ALDH1A1 1233/4885ALOX15 2530/4885 |
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | PIK3CA, PIK3CB, PI4KA | KDM4E 1629/4885ALDH1A1 4729/4885ALOX15 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.